Biopôle SA is partnering with Labcorp, a leading global life sciences company, to promote access to—and growth of—emerging technologies and innovative services.

The arrangement builds on the two companies’ past collaboration, offering enhanced visibility to Biopôle’s vast network of European biotechnology and life sciences startups. It also provides Labcorp with an additional avenue for identifying potential partnership and investment opportunities that could further its mission to improve health and improve lives.

Through this partnership, Biopôle SA will hand-pick innovative startups from its network that could potentially enhance Labcorp’s diagnostics and drug development services, support strategic objectives, or help address an unmet or future need. Those startups would then be connected with Labcorp to present their novel science and technology for consideration.

Labcorp is a Fortune 250 and S&P 500 company headquartered in Burlington, North Carolina, and operating in more than 100 countries. It harnesses a unique combination of diagnostics and drug development capabilities to generate key insights that inform critical decisions made by patients, health care providers and pharmaceutical companies. The company, which has more than 70,000 employees, continues to forge a global reputation for innovation and technological achievement.

Biopôle SA, a life sciences community with a world-class combination of infrastructure, professional networking, value-add services and community engagement, is committed to helping its members thrive. Its work with Labcorp is the latest in a series of corporate partnerships intended to bridge the gap between large corporations and startups.